FDA Extends Review Period for Belite Bio's Stargardt Disease Drug
1 report, 1 independent
Updated Fri 13:45
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The U.S. Food and Drug Administration informed Belite Bio, Inc. that it has extended the review period for the New Drug Application (NDA) for tinlarebant by three months. The extended action date is now May 12, 2027. If no major deficiencies are found during the review, the FDA plans to communicate proposed labeling requests by April 12, 2027.
From manilatimes.net
Why it matters
The extension provides the FDA with additional time to review the clinical evidence supporting tinlarebant, an oral therapy intended to treat Stargardt disease type 1. The timeline for this drug's potential market entry is now adjusted.
From manilatimes.net
Who's involved
- FDAThe regulatory agency that extended the review period for the drug application.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- FDA delay may prompt adjustments to EMA's global coordination effortsFDA review delay may prompt adjustments to EMA's global coordination effortsPossible
- How could the FDA's extended review period affect the company's market timeline?Belite Bio's drug market entry may be delayed by three monthsPossible
- Belite Bio NDA extension may increase Center for Drug Evaluation and Research workloadThe review extension may increase the operational timeline for the Center for Drug Evaluation and Research.Possible
Keep exploring
The entities involved
Related events
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.
- FDA failed to update warning labels despite confirmed risks associated with a product.